Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia

Next Previous
Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation

    • Most Recent Events

    • 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Sep 2014 Results of a retrospective analysis including patients with both homozygous and heterozygous familial hypercholesterolemia treated for one year were presented at the 2014 European Society of Cardiology Congress, according to an Isis Pharmaceuticals media release.
    • 29 Mar 2012 Interim results presented at the 16th International Symposium on Atherosclerosis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top